Patient characteristics
MAY
117 patients were screened between November 30, 2020 and May 28, 2021 in 14 trial sites across Germany. 111 patients were randomized; 55 (50%) to the rivaroxaban-group and 56 (50%) to the group with standard of care (SOC) group, in which a heparin was administered at a prophylactic dose. Baseline characteristics were similar between groups (Tables Baseline characteristicsBaseline medication and laboratory parametersThe baseline characteristics in the subgroup of patients with a Baseline characteristics (Baseline medication and laboratory parameters (